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26-WEEK EXTENSION OF A 26-WEEK TRIAL OF
INTRA-ARTICULAR HYALURONATE (EUFLEXXA®) IN
OSTEOARTHRITIS OF THE KNEE (THE FLEXX TRIAL)
R.D. Altman1, J.E. Rosen2, P. Korner3
1UCLA, Agua Dulce, CA; 2New York Hosp., Queens, New York,
NY; 3Ferring Pharmaceuticals Inc., Parsippany, NJ
Purpose: The FLEXX trial was a 26-week, double-blind, ran-
domized, saline-controlled study of osteoarthritis (OA) knee pain
treated with an intra-articular (IA) bioengineered 1% sodium
hyaluronate (Euﬂexxa® , IA-BioHA). Patients completing the 26-
week, double-blind phase (core study) were eligible to participate
in the extension phase and received a 3-injection series of IA-
BioHA to evaluate safety. Secondary measures included pain
experienced after a 50-foot walk, the 3 subscales of the WOMAC,
OARSI responder criteria, Patient Global Assessment, use of res-
cue medication, and the SF-36.
Methods: At the ﬁnal visit (week 26) of the core study, all patients
had the option of participating in the open-label extension phase of
the study. Those who elected to participate in this phase received
a once-weekly injection of IA-BioHA into the target knee for 3
weeks (Weeks 26, 27 and 28). Patients returned to the study
center at Weeks 41 and 52 for evaluation. They were also called
by phone at Week 34 or 35 to conﬁrm progress and maintain
contact. The total period of the extension study was 26 weeks,
with 5 clinic visits.
Results: Of the 588 patients (safety population) who participated
in the core study, a total of 433 (73.6%) entered the open-label
extension phase of the FLEXX Trial. The proportions of patients
coming from the core IA-BioHA group [214 (74.7%)] and core
Saline group [219 (72.5%)] were similar, and 87% of both groups
completed the extension. Adverse events were reported in 43% of
both groups. Only 5% were considered IA-BioHA related: arthral-
gias 2.8%, joint swelling 1.2%, peripheral edema 0.7%, injections
site pain 0.5%. There was no difference in adverse reactions
between study groups. No patients reported the treatment emer-
gent adverse event of joint effusion during the extension study.
Retreatment with IA-BioHA was associated with modest further
improvement in pain scores on the 50-foot Walk Test and other
core study measures of efﬁcacy (Table 1).
Table 1. Pain reported following 50-foot walk on a 100mm VAS*
Baseline 26 weeks 28 weeks 41 weeks 52 weeks
IA-BioHA/IA-BioHA 56±22 30±26 22±20 23±24 31±27
*For baseline before ﬁrst injection series and at 26 weeks before second injec-
tion series.
Conclusions: Reinjection with IA-BioHA was well tolerated and
provided a modest further improvement in pain and function from
the ﬁrst injection series over an additional 26 weeks. There was
no difference in adverse event proﬁles for those receiving their ﬁrst
IA-BioHA injection vs. those receiving reinjection.
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DEGRADATION OF HYALURONAN BY IODINATED
CONTRAST MEDIA
G. Mendoza1, J.A. Sanchez-Lazaro2, P. Coronel3, M. Gimeno3,
J.G. Prieto1
1Univ. of Leon, Leon, Spain; 2Dept. of Orthopaedics, Hosp. of
Leon, Spain, Leon, Spain; 3Tedec Meiji Farma, Madrid, Spain
Purpose: One of the main events in osteoarthritis is the decrease
in viscosity and elasticity of the synovial ﬂuid, mainly due to
reductions in hyaluronan concentration and molecular weight, and
therefore its ability to protect the joint is lessened. Although several
options are available for the treatment of osteoarthritis, one of the
most important is viscosupplementation, which involves the intra-
articular injection of hyaluronan, restoring synovial ﬂuid viscosity,
thereby reducing pain and recovering function. Hyaluronan is
administered in several affected joints, including the hip. In this
case, iodinated contrast media are used prior to the hyaluronan
injection to verify the correct positioning of the needle in the
intra-articular space. The aim of this study was to determine the
possible interaction between both products and the inﬂuence of
iodinated contrast media on hyaluronan.
Methods: Samples of hyaluronan (molecular weight about 1000
kDa) containing different amounts (0.5, 0.75 and 1 ml) of iodinated
contrast medium (ioxaglate meglumine), with and without previous
incubation for 24 hours at 37°C, were tested. Change in hyaluronan
molecular weight was observed by size-exclusion chromatography.
Hyaluronan degradation and molecular weight were estimated
from the retention times observed.
Results: Hyaluronan molecular weight of end-products showed
that hyaluronan suffers degradation when it is used together with
iodinated contrast media. The decrease in molecular weight was
higher in incubated samples, with a loss in molecular weight of 27-
29%, while samples not incubated showed a decrease of around
19-23%. In fact, differences of 4.6% (0.5 ml iodinated contrast
medium), 5.3% (0.75 ml iodinated contrast medium) and 9.3%
(1 ml iodinated contrast medium) were found between the same
sample subjected and not subjected to temperature for 24 hours.
These values therefore exerted signiﬁcant differences between
incubated and non-incubated samples, but no differences were
found among the volumes of iodinated contrast medium assayed.
Conclusions: It is proposed that the components of the iodinated
contrast medium analysed may interact with hyaluronan molecule,
breaking the glycosidic bonds between its monomers and pro-
ducing signiﬁcant degradation, which could result in a reduction
of clinical efﬁcacy. The results of clinical studies conducted with-
out taking into account this interaction should be considered with
caution.
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TIMP-3 BINDS DIRECTLY TO THE LRP-1 SCAVENGER
RECEPTOR, AND BLOCKING THIS INTERACTION
PROMOTES TIMP-3 ACCUMULATION
P. Li1, A. Bakker1, K. Moore1, K. Allen1, K. Dang1,
K. Poindexter2, K. Schooley2, S. Catania3, D. Strickland3,
R.A. Black2
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Purpose: TIMP-3 inhibits all the major cartilage-degrading metal-
loproteases, and multiple lines of evidence indicate that it protects
cartilage. Addition of the protein to cartilage explants prevents
cytokine-induced degradation, and intra-articular injection reduces
cartilage damage in the rat medial meniscal tear model of os-
teoarthritis. Conversely, TIMP-3 knockout mice spontaneously de-
velop cartilage lesions. While the results with injected TIMP-3 are
encouraging, frequent injections are required because the protein
is rapidly cleared. To facilitate the therapeutic use of recombinant
TIMP-3, we are investigating the clearance mechanism. Follow-
ing reports that blocking the LRP-1 scavenger receptor causes
an accumulation of TIMP-3, we asked whether TIMP-3 binds di-
rectly to LRP-1 and whether blocking this interaction is sufﬁcient
to promote TIMP-3 accumulation. We also sought to conﬁrm the
proposed mechanism for TIMP-3 clearance by evaluating accu-
mulation in cultures of LRP-1 deﬁcient cells and by using confocal
microscopy to visualize internalization of the protein.
Methods: Various sequences from the ecto-domain of LRP-1 were
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expressed in E. coli and tested for binding to TIMP-3 by both plate-
and bead-based binding assays. Sequences that bound TIMP-3
were tested for interference with TIMP-3’s inhibition of MMP-13,
using a ﬂuorescence-quench substrate, and for promotion of TIMP-
3 accumulation in HTB-94 cell cultures. TIMP-3 in the media was
assayed by western blot and ELISA. Internalization of exogenous
TIMP-3 was examined by confocal microscopy with A549 cells:
cells were incubated typically with 1 ug/ml TIMP-3 for 30 minutes
at 4 degrees, with or without various pre-treatments, then washed,
ﬁxed and stained with a ﬂuorescently labeled anti-TIMP-3 antibody,
or washed and then incubated further at 4 or 37 degrees before
ﬁxation and staining.
Results: Multiple ecto-domain LRP-1 sequences bound TIMP-3
with submicromolar afﬁnity, including Cluster II (which contains
8 ligand binding domains) and parts of Cluster IV. The Cluster
IV sequences substantially impaired TIMP-3’s inhibition of MMP-
13, but Cluster II had a minimal effect on this inhibitory activity.
Moreover, Cluster II caused an accumulation of TIMP-3 in HTB-
94 cell cultures comparable to that seen in the presence of
heparin, which is believed to prevent TIMP-3 from binding to the
cell surface. Cells that lack LRP-1 were found to accumulate
TIMP-3 in the medium to a greater extent than wild-type cells.
The confocal microscopic analysis showed that TIMP-3 binds
to the cell surface by a heparin-competible mechanism, rapidly
disappears when the cells are incubated at 37 degrees but not at
4 degrees, and accumulates inside the cells if they are pre-treated
with chloroquine to prevent lysosomal degradation.
Conclusions: TIMP-3 can bind directly to the LRP-1 scavenger
receptor. Some TIMP-3-binding fragments of the receptor reduce
the inhibitor’s activity against metalloproteases, but others do not,
and one of these causes an accumulation of TIMP-3 in tissue
culture medium. LRP-1 is required for normal clearance of TIMP-
3, which entails binding to the cell surface, internalization, and
degradation by lysosomes.
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COMPARATIVE EFFICACY AND SAFETY OF TWO
DIFFERENT MOLECULAR WEIGHT (MW) HYALURONANS
F60027 AND HYLAN G-F20 IN KNEE OSTEOARTHRITIS
(KOA): A NON-INFERIORITY RANDOMISED CONTROLLED
TRIAL
E. Maheu1, M. Zaïm2, T. Appelboom3, S. Jeka4, T. Trc5,
K. Maasalu6, M. Hucher7, F. Berenbaum1
1Rheumatology - St Antoine Hosp., Paris, France; 2Clinical
research, Pierre Fabre Labs, Ramonville, France; 3Rheumatology,
Erasmus Hosp., Bruxelles, Belgium; 4Rheumatology, Nzoz "Nasz
Lekarz", Torun, Poland; 5Orthopedics, Ortopedickài klinika UK2
LF, Prague, Czech Republic; 6Orthopedics, Ortopeedia Ja
Kliniliste Keskus, Tartu, Estonia; 7Biometry, Pierre Fabre Labs,
Labege, France
Purpose: Background: Several Hyaluronic acids (HA) are cur-
rently available for the management of KOA. Some assertions
have been made regarding a potential better efﬁcacy of the high-
est MW products. However, results of existing published trials are
controversial.
Objectives: To compare the efﬁcacy and safety of a "medium" MW
(F60027, Structovial) and a "high" MW (Hylan G-F 20, Synvisc)
HA on function and pain in KOA.
Methods: We conducted a multicentre, double-blind (injector and
clinical assessor blinded to each other), active controlled, parallel-
group study, according to a non-inferiority design. Patients aged 50
- 75 years with symptomatic KOA (ACR criteria) were randomized
to receive 3 intra-articular injections at weekly intervals of either
F60027 or Hylan G-F20. Inclusion criteria were: global pain in
the target knee > or = 40 mm on a 100-mm visual analog scale
(VAS), Lequesne’s Algofunctional Index (LFI) score > 7 (range: 0-
24) and radiological Kellgren-Lawrence grade 2 or 3. The primary
outcome was the LFI score change between baseline and week
24. Secondary assessments were pain VAS, quality of life (SF-12),
patient’s and physician’s global assessments on VAS at baseline,
weeks 1, 2, 6, 12, 18 and 24. Safety was assessed by recording
any adverse events. A non-inferiority test was assessed: 95%
conﬁdence interval (CI) of the difference F60027 - Hylan G-F20
on change of LFI score. Pre-determined non inferiority limit was
settled as the lower limit of the 95% CI above -1.25.
Results: 279 patients were randomized: 276 analyzed in the full
analysis dataset (FAS), 236 in the per protocol (PP) analysis. No
difference between groups at entry regarding demographics and
disease characteristics. The main efﬁcacy analysis (PP) showed
no difference between F60027 and Hylan G-F20 on mean vari-
ations of the LFI score over 24 weeks which varied by -4.67
(0.27) in F60027 group and -4.54 (0.28) in Hylan G-F20 group ;
difference = 0.132 [95%CI: -0.598, 0.861]. The -0.598 lower limit
of the CI was above the pre-trial selected non inferiority margin
of -1.25, which clearly demonstrated the non inferiority of F60027
compared to Hylan G-F20. The analysis on the FAS gave similar
results. Analyses of the secondary efﬁcacy endpoints on both
PP/FAS populations showed the same trends for each treatment
with improvements of clinical relevance of all outcomes at week
24. Improvement on function and pain translated into an improve-
ment on the physical component of SF12. Maximum improvement
was achieved at week 6 and maintained up to week 24. Changes
of the LFI score between baseline and week 24 were -5.73 in
the F60027 group and -5.57 in the Hylan G-F20 group giving an
intra-group effect size of 1.48 and 1.44 respectively.
Both treatments were well tolerated. Local reactions such as pain
at injection site were reported in 3.6% of patients in each group.
Conclusions: F60027 and Hylan G-F20 were equally effective in
reducing functional impairment and pain over a 6 month period of
time in KOA patients, without any safety concerns.
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CONCOMITANT COMBINATION INTRA-ARTICULAR
HYALURONIC ACID AND CATIONIC ARTICULAR BRACE
THERAPY FOR ADVANCED OSTEOARTHRITIS OF THE
KNEE: A CASE REPORT
J.P. Figueroa
Harrington Mem. Hosp., Southbridge, MA
Purpose: Intra-articular hyaluronic acid (HA) injections of the knee
have been established to both lubricate and replenish the surface
cartilage of the knee joint. This is accomplished when HA stim-
ulates chondrocytes to produce a substance that is similar to
cartilage. The cationic articular brace (CAB) functions by stimulat-
ing chondrocytes at a particular electromagnetic frequency which
can lead to the production of more cartilage. Over the course of
two years approximately 30% of patients treated with this brace
can demonstrate an increase in joint space by MRI associated
with functional and symptomatic improvement.
In this case presentation of advanced osteoarthritis of the knee,
serial intra-articular HA injections when tried singularly provided
only minimal pain relief. The patient’s cardiac status eliminated
surgery as a therapeutic option. Symptomatically the patient’s
pain severely impaired his ability to ambulate. It was only when
the concomitant combination of intra-articular HA injections and
CAB therapy was used for his knee that the patient’s pain was
sufﬁciently relieved such that he was able to increase his ability to
ambulate.
Methods: For approximately a 1 year period the patient recieved
2 cycles of intra-articular HA injections to both knees. The symp-
tomatic and functional beneﬁt was noted. Then over a 2 year
